As the leader of two separate Clinical Team Grants, Dr. Gnjatic is working with several others to improve the benefits of immunotherapy for patients.
One project, in collaboration with Nina Bhardwaj, M.D., Ph.D., is investigating how checkpoint immunotherapy interacts with chemotherapy as well how mutations influence its effectiveness in advanced bladder cancer. They’ve already uncovered several insights relating to altered immune cell and antibody activity, and plan to use these to guide vaccine development and inform combination treatment approaches.
The other project, in collaboration with Andrew G. Sikora, M.D., Ph.D., Christine Chung, M.D., and Nham Tran, Ph.D., is working to improve the immune-stimulating effects of chemo-radiotherapy (CRT) in HPV-associated head and neck cancer, by targeting the tumor microenvironment (TME). This involves analyzing patient samples before and during CRT, using mouse models of HPV-associated cancer to test different CRT dosing regimens and combinations.
Projects and Grants
The mutation-derived tumor antigen landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy
Icahn School of Medicine at Mount Sinai | Bladder Cancer | 2015
Targeting the tumor immune microenvironment to enhance immune-stimulating effects of chemoradiotherapy
Icahn School of Medicine at Mount Sinai | Head and Neck Cancer | 2015
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.